Clinical Trial Update: Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update evaluating the safety and efficacy of benralizumab for hypereosinophilic syndrome across Phase 2 and Phase 3 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypereosinophilic Syndrome

Drugs mentioned

• Benralizumab (benralizumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Respiratory System Agents, Anti-Asthmatic Agents | Phase 2, Phase 3 | Status: UNKNOWN | Results posted: 2022-02-08